• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • DeviceTalks Weekly
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » Aethlon’s blood filtration device as broad countermeasure for infectious diseases

Aethlon’s blood filtration device as broad countermeasure for infectious diseases

November 18, 2016 By Sarah Faulkner

Aethlon's blood filtration device as broad countermeasure for infectious diseaseIn the midst of a devastating global crisis 2 years ago, a Ugandan physician was infected with Ebola in Sierra Leone as he was treating patients. He was hospitalized at the Frankfurt University Hospital and 12 days later he was unconscious, suffering from multiple organ failure.

By the time Aethlon Medical (NSDQ:AEMD) got permission to use its Hemopurifier device, the doctor required mechanical ventilation, continuous dialysis and vasopressor medications. After almost 7 hours of treatment with the single cartridge blood filtration device, the patient’s viral load dropped from 400,000 virus copies per milliliter of blood to 1,000 copies per milliliter. The doctor eventually made a full recovery.

Aethlon CEO Jim Joyce told MassDevice.com that this story is a powerful example of what the device can do for viruses that do not have a known vaccine. He also pointed out that the “one bug, one drug” approach that scientists have used for years is not always the most efficient way to combat infectious disease outbreaks.

“There’s just not enough candidates, realistically, to address these threats and many of the threats you don’t know what’s going to evolve next. As an example, Zika has been known since 1947, but no one could have predicted that it was going to unfold and become a threat at the pace that it did,” he said. “In reality, if you go to FDA’s own website, it would indicate that maybe 5 of every 5,000 drug candidates that initiate studies are approved for clinical studies and of those, 1 would be expected to be approved.”

The search for a broad-spectrum countermeasure to combat viruses is becoming increasingly urgent, as threats like Ebola and Zika have rocked the global health infrastructure in the last several years.

“From a congressional standpoint on Capitol Hill, we started talking about the need for a broad-spectrum countermeasure to address these threats more than a decade ago,” Joyce said.

The San Diego-based company’s Hemopurifier device is a single-use, disposable cartridge designed to target and filter out viruses or tumor-secreted exosomes. Blood flows through the cartridge into nearly 3,000 hollow fibers with pores 250 nanometers in diameter. A pressure deferential in the 1st third of the fiber pushes particles below 250 nanometers through the pores into a space between the fibers and the cartridge.

There an affinity agent binds to a disease-specific structure associated with viruses. The structure is something viruses co-opt from the host’s own cells during replication to avoid detection from the host’s immune system. But within the device, that signature is what binds viruses to the cartridge. Everything else continues to flow through the device.

Aethlon CEO Jim Joyce
Joyce

“It’s a single-use, disposable cartridge and it’s blood in, blood out. We’re not pulling out plasma, then treating it, or anything of that nature,” Joyce told us. “The blood flows into the cartridge at about 200 milliliters a minute, so for your average-size individual the entire circulatory system might turn over through the cartridge about once every 15 minutes.”

The company is wrapping up a Phase I feasibility study, with plans to begin pivotal studies required for commercialization. With pathogens for which it’s impossible to run controlled clinical studies, Joyce said the company will pursue Humanitarian Use Device pathways. The Hemopurifier is approved for emergency use in treating Ebola in the U.S. and Canada.

“We think [the device] can be significantly important strategy in the case of viral pathogens where there isn’t a proven drug or vaccine to tip the balance in favor of the immune system,” Joyce said. “In cases where drugs and vaccines do exist, the work is an adjunct that can combine with other therapies without adding additional drug toxicity, yet it proves potential benefit of those therapies.”

Aethlon has conducted 4 studies overseas using the device with HIV and hepatitis C patients, as well as studies to capture H1-N1 swine flu virus, the H5-N1 bird flu virus, and even the reconstructive Spanish Flu of 1918. The company has also confirmed capture of chikungunya, West Nile virus and recently had its 1st data point demonstrating capture of Zika virus. Aethlon has also demonstrated in in vitro studies that its Hemopurifier device can capture tumor-derived exosomes.

“We’ve been very active in validating behind the scenes that indeed, our cartridge is broad-spectrum – and broad-spectrum in the sense that it’s not broad-spectrum against different strains of the same virus, but it’s actually broad-spectrum across different strains, species and families of viral pathogens,” Joyce explained.

As the company wrapped up its fiscal 2nd quarter ending Sept. 30, it faced a net loss of -$2.3 million, or -29¢ per share, compared to a net loss of -$1.2 million, or -16¢ per share in the same period last year.

“As we’re a clinical-stage company, some of the highlights aren’t truly impressive from a financial standpoint, but I think the key takeaway is that we’re closing in on completing our FDA-approved feasibility study for our Hemopurifier, which we believe is the 1st study of its kind to be approved by FDA for clinical studies.”

The company also hit all 29 milestones in its U.S. Defense Dept. contract with the Defense Advanced Research Projects Agency, which has generated about $5.9 million in revenue to date.

Joyce added that he’s proud that Aethlon has maintained a low burn rate over the years, keeping it to roughly $300,000 a month.

“Maintaining a low burn rate is historically really important for survival, and we’ve recognized that it gives us tremendous flexibility when we don’t have to stare down a need to keep running back to the financial market to raise tens of millions of dollars to support the advancement of a therapeutic,” he said. “We don’t expect the burn to change at any point in time in the next quarter or so, but we do expect it’ll ramp up as we continue to advance into larger clinical studies of different disease indications.”

Filed Under: Blood Management, Food & Drug Administration (FDA), Research & Development Tagged With: Aethlon Medical Inc., MassDevice Q&A

In case you missed it

  • CeQur raises $115M for wearable insulin delivery device
  • Survey shows solid medical device industry performance despite pandemic
  • Cardinal Health wins $58M federal PPE contract
  • SentiAR closes $5.1M Series A
  • Endologix acquires PQ Bypass
  • Could BrainCheck’s simple test help COVID long-haulers?
  • Feds halt J&J COVID-19 vaccine due to blood clot concern
  • BioCorp, Roche launch Mallya smart insulin pen in France
  • The top 5 pharma firms by reputation
  • Famed marathoner uses Abbott glucose sensor for training
  • Medical device companies put $3.6 billion in docs’ pockets, study finds
  • DiaSorin to buy Luminex for $1.8B
  • Genentech wins FDA approval for Xolair prefilled syringe
  • FDA slaps Class I label on rapid infuser recall
  • Microsoft spending $19.7B on Nuance and its AI for healthcare providers
  • Memic raises $96M to support surgical robot with humanoid-shaped arm
  • Heater-Cooler suit against LivaNova revived

RSS From Medical Design & Outsourcing

  • Micro to add plant in Costa Rica
    Contract manufacturer Micro today announced plans to open a new plant in Costa Rica. The 32,000 ft² facility will significantly increase Micro’s cleanroom assembly capacity, according to the Somerset, N.J.-based company. It will be located in the Zona Franca Metro business park and is expected to open in late 2021 with operations beginning in 2022.… […]
  • Survey shows solid medical device industry performance despite pandemic
    By Stewart Eisenhart, Emergo Group Medical device and IVD manufacturers report healthy performance over the course of 2020, but also faced significant operational and regulatory challenges related to the coronavirus pandemic. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s only and do not… […]
  • Cardinal Health wins $58M federal PPE contract
    Cardinal Health (NYSE: CAH) today said it has won a $57.8 million contract from the U.S. Dept. of Health and Human Services to support the Strategic National Stockpile. The Dublin, Ohio-based company received the contract, which includes options that if exercised by the HHS could reach $91.6 million, to store and distribute 80,000 pallets of… […]
  • Qosina adds single-use bioprocessing devices
    Qosina this week launched its product line for the single-use bioprocess industry. The new product line includes tube-to-tube bard connectors, luer fittings, check valves, tubing pinch clamps, tubing, steam thru connectors and more. Get the full story on our sister site, Medical Tubing + Extrusion. The post Qosina adds single-use bioprocessing devices appeared first on […]
  • Could BrainCheck’s simple test help COVID long-haulers?
    BrainCheck‘s eponymous mobile neurocognitive test can detect dementia and concussion. But it has a new application: post-COVID brain fog. Developed by neurologists at Baylor College of Medicine’s Eagleman Laboratory for Perception and Action, BrainCheck carries an FDA Class II Software as a Medical Device (SaMD) designation and can be used on a tablet or laptop… […]
  • XL Precision Technologies holding an April 28 webinar about laser tech
    XL Precision Technologies is holding an online webinar on April 28 at 8 a.m. Eastern time (1 p.m. U.K. time) about laser technology in medical device manufacturing. Register for the webinar here: https://bit.ly/XL-MER-Webinar2 Stockton-on-Tees, U.K.–based XL Precision Technologies provides laser welding, laser cutting of fine tubes and flat material and laser etching of components. It’s… […]
  • Medical device companies put $3.6 billion in docs’ pockets, study finds
    Medtech companies paid $3.62 billion for access to physicians — 10% more than drug companies did — from 2014 to 2017, according to new research. Device company payments to surgical specialists were significantly more tied to the surgeons’ Medicare billing than payments from drug companies to specialists, according to the study, which appears in the… […]
  • FDA slaps Class I label on rapid infuser recall
    The FDA today declared that the recall of an emergency infusion device kit is the most serious type. The recall covers three models of disposable sets made by Smisson-Cartledge Biomedical for its ThermaCor 1200 rapid infuser, which is used for fluid or bolus delivery. The system is made of a footswitch for hands-free fluid control,… […]
  • Cretex breaks ground on new plant north of Minneapolis
    Cretex Cos. last week broke ground on a new 245,000 ft2 medical device contract manufacturing plant in Brooklyn Park, Minn. Elk River, Minn.–based Cretex plans to complete facility construction by the end of the year. The company expects the facility by the end of 2022 to house its stamping, molding and tool design — and… […]
  • Resonetics to expand manufacturing in Costa Rica
    Resonetics announced today it has leased new manufacturing space in Costa Rica to more than double its production there. The space, in a building near its current site in the Coyol Free Zone business park in Alajuela, will be expanded and reconfigured to create a 45,000 ft² production site. The move comes after the company… […]
  • Are Black patients not getting LVADs as quickly as white patients?
    Researchers from the University of Missouri conducted a study that found disparities in treating Black and white patients with advanced heart failure. According to a news release, the study found that Black patients with advanced heart failure were more likely to receive a left ventricular assist device (LVAD) — a pump implanted into the chest… […]

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS